ZNF703 and breast cancer: In other terms, because ZNF703 is an oncogene originally identified in luminal BC [34,38], we wanted to see if inhibition of ZNF703 expression combined with cisplatin could improve the therapeutic efficacy of ZNF703-ASO9 in our luminal B model (MCF7-ZNF703/GFP) [34].